Citations

Clear

4610 citation(s) found for "Lu, Brian".

Identification of Surrogate Outcome Biomarkers in Lung Allograft Recipients With Bronchiolitis Obliterans: Implications for Randomized Controlled Trials
Hage, Chadi A. , Goldberg, Hilary J. , Patel, Mrunal, Reynolds, John M. , Klesney‐Tait, Julia , Arcasoy, Selim M. , Naik, Chetan , Simone, Nicole De , Usmani, Amena , Girgis, Reda E. , Cordova, Francis , Patil, Jagadish , Morrell, Matthew R. , Lendermon, Elizabeth A. , Huang, Howard J. , Peláez, Andrés, Emtazoo, Amir, Wille, Keith , Chan, Kevin M. , Yung, Gordon , Baz, M., Aryal, Shambhu , Derfler, Mary Clare, Commean, Paul K., Berman, Keith, Прокудин, А. В. , Despotis, George J. , Group, The EPI Study, Baz, Maher, Byers, Derek E. , Hachem, Ramsey R. , Walia, Rajat , Keller, Brian C. , Nunley, David R. , Baz, Maher, Vedantham, Suresh , Atkinson, Andrew , Atkinson, Jeffrey J. , Prokudin, Alexey, McCarthy, John Edward , Group, The EPI Study

Mayo Clinic

Transplantation Direct | September 19, 2025 | Volume: 11 | Issue: 10 | Pages: e1857

10.1097/txd.0000000000001857 | PMID 40989076 Get It

BACKGROUND. We developed a prospective, multicenter “registry” to evaluate the effect of extracorporeal photopheresis for lung transplant recipients who develop chronic lung allograft dysfunction (CLAD) with the bronchiolitis obliterans syndrome (BOS) phenotype (CLAD/BOS) and who are refractory to conventional standard-of-care therapy. METHODS. Data from 258 lung transplant recipients enrolled in the Registry between April 2015 and April 2022 were included in this analysis. All recorded parameters (eg, demographics), including forced expiratory volume in 1 s (FEV1) measurements and indices (FEV1% baseline, FEV1 rate of decline) at several time periods, were included in multivariate linear/logistic and Kaplan-Meier analyses to evaluate potential associations with survival. RESULTS. Mortality at 6 and 12 mo after CLAD/BOS diagnosis was 5% and 14%, whereas mortality at 6 and 12 mo after enrollment was 15% and 26%, respectively. The primary cause of death in the cohort was respiratory failure or graft failure (74%). Rate of FEV1 decline (log) at enrollment was independently associated with survival (log days) from CLAD/BOS diagnosis and enrollment (r = 0.55 and r = 0.3, respectively). The rates of FEV1 decline among survivors were lower (–77 ± 89 mL/mo) compared with nonsurvivors (–148 ± 155 mL/mo) at 6 mo after enrollment (P = 0.0001). CONCLUSIONS. The rate of FEV1 decline quantified using at least 5 FEV1 measurements is a robust surrogate outcome. We plan to use these findings to revise our randomized controlled trial to facilitate risk adjustment using FEV1 rate of decline strata at enrollment and as a scientifically valid surrogate for outcome.
Procedure duration predicts outcomes more than prehospital delay in endovascular stroke treatment
Saad, Hassan , Koo, Andrew B. , Grossberg, Jonathan A , Tianwen, Ma, Howard, Brian M. , Sowlat, Mohammad‐Mahdi , Baba, Bachar El , Chacón, Ariana , Jabbour, Pascal , Rai, Ansaar , Dye, Justin , Alaraj, Ali , Cawley, C. Michael , Tong, Frank , Akbik, Feras , Pabaney, Aqueel, Ezzeldin, Mohamad , Kim, Joon‐Tae , Siddiqui, Fazeel , Maier, Ilko , Park, Min S. , Psychogios, Marios‐Nikos, Wolfe, Stacey Q , Starke, Robert M. , Tanweer, Omar , Polifka, Adam , Mokin, Maxim, Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard , Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Spiotta, Alejandro M , Ma, Tianwen , El Baba, Bachar , Fiorella, David , Yoshimura, Shinichi , Kim, Joon-Tae , Arthur, Adam Stephen , Fragata, Isabel , Siddiqui, Fazeel M , Matouk, Charles , Maier, Ilko , Levitt, Michael R , Grandhi, Ramesh , Wolfe, Stacey Quintero , Shaban, Amir , Navia, Pedro , Osbun, Joshua W , Brinjikji, Waleed , Altschul, David J , Ogilvy, Christopher S , Crosa, Roberto , Paul, Alexandra R , Kan, Peter , Spiotta, Alejandro M , Alawieh, Ali M , Alaraj, Ali , Sowlat, Mohammad-Mahdi , Howard, Brian M , Koo, Andrew B , Chacón-Aponte, Ariana Alejandra , Jabbour, Pascal , Fiorella, David , Yoshimura, Shinichi , Goyal, Nitin , Fragata, Isabel , Mascitelli, Justin R , Matouk, Charles , Levitt, Michael R. , Grandhi, Ramesh , Samaniego, Edgar A , Romano, Daniele G, Navía, Pedro , Cuellar, Hugo , Moss, Mark E, Limaye, Kaustubh , Mokin, Maxim , Gory, Benjamin , Alawieh, Ali

Mayo Clinic

Journal of NeuroInterventional Surgery | September 19, 2025 | Volume: 18 | Issue: 6 | Pages: 1494-1502

10.1136/jnis-2025-023906 | PMID 40973492 Get It

Background Endovascular thrombectomy (EVT) has transformed acute ischemic stroke (AIS) care, with onset-to-puncture (OTP) time widely recognized as a critical determinant of outcome. However, emerging evidence suggests that in-hospital procedure time (PT)—from arterial puncture to final recanalization—may have an equally or more significant impact. This study examines the relative contribution of PT versus OTP to functional outcomes in patients with AIS undergoing EVT. Methods A retrospective analysis was conducted of 6644 patients with AIS treated at 44 international stroke centers from the Stroke Thrombectomy and Aneurysm Registry (STAR; 2016–2023). Multivariable regression, time-equivalence analysis, and marginal effects modeling were used to assess associations between PT, OTP, and 90-day modified Rankin Scale (mRS) outcomes. Centers were stratified by procedural efficiency and compared using propensity score matching (PSM). Mediation analysis evaluated whether PT accounted for inter-center differences. Results PT and OTP were independently associated with functional outcomes; however, PT had a significantly stronger effect (adjusted OR for mRS 0–2: PT=0.56 vs OTP=0.96 per hour). Each 5 min increase in PT was equivalent to 78–100 min of additional OTP in outcome impact. Centers with faster average PT had higher rates of functional independence (number needed to treat (NNT)=10), fewer complications, and lower symptomatic intracranial hemorrhage rates. PT significantly mediated the relationship between center tier and outcomes (Sobel’s P<0.001). Conclusion While minimizing OTP remains important, PT exerts a greater influence on outcomes after EVT. Procedural efficiency should be emphasized in stroke systems of care and included in center performance metrics to improve patient outcomes.
Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma
Ramsower, Colleen , Wright, George W. , Cerhan, James R. , Maurer, Matthew J. , Mwangi, Raphael , Novak, Anne J. , Link, Brian K. , Witzig, Thomas E. , Smith, Sonali M. , Friedberg, Jonathan W. , Rimsza, Lisa M. , Witzig, T.E. , Ramsower, Colleen A , Wright, George , Cerhan, James R , Maurer, Matthew , Rosenthal, Allison , Novak, Anne J , Link, Brian K , Kridel, Robert , Shadman, Mazyar , Smith, Sonali M , Friedberg, Jonathan W , Scott, David W , Steidl, Christian , Rimsza, Lisa M , Li, Hongli , Habermann, Thomas M. , LeBlanc, Michael , Shadman, Mazyar , Scott, David W. , Steidl, Christian

Mayo Clinic

Blood Advances | September 18, 2025 | Volume: 9 | Issue: 24 | Pages: 6443-6454

10.1182/bloodadvances.2025016827 | PMID 40966421 Get It

Abstract Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events, such as transformation or progression, have increased risk of death related to lymphoma. The FL24Cx is an algorithm based on a 45-target gene expression profiling (GEP) assay, which was developed and trained using 265 formalin-fixed, paraffin-embedded tissue samples on a reliable platform to predict, at the time of diagnosis, whether a patient will experience an event within 24 months. The modeling also confirmed and relied upon previously reported synergy between immune response (IR) gene expression signatures IR1 and IR2. Once locked, the 5-factor logistic regression FL24Cx model was independently validated in a retrospectively assessed cohort of 232 patients from 2 immunochemotherapy-treated arms of SWOG Cancer Research Network S0016 phase 3 clinical trial, in which it assigned 169 patients to the low-risk group with 29 events before 24 months (17.2%) and 63 patients to the high-risk group with 24 events before 24 months (38.1%). The relative risk of an event within 24 months after registration among patients who were classified into the high-risk group relative to patients who were classified into the low-risk group was 2.2 (95% confidence interval, 1.41 to 3.51). An up-front GEP biomarker, such as the FL24Cx, rigorously validated in a clinical laboratory and with a clinically relevant turnaround time, could identify and steer enrollment of patients at high risk for early events in clinical trials, thus enabling timely interpretation of such trials and increasing the pace of innovation.
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Blechter, Batel , Wang, Xiaoyu , Karsonaki, Christiana, Shi, Jianxin , Shiraishi, Kouya , Choi, Jiyeon , Matsuo, Keitaro , Chen, Tzu‐Yu , Kim, Young Tae , Choudhury, Parichoy Pal , Williams, Jacob , Landi, Maria Teresa , Yin, Zhihua , Zhou, Baosen , Seow, Wei Jie , Song, Lei , Chang, I‐Shou , Chien, Li-Hsin , Wong, Maria Pik , Richardson, Brian Douglas , Li, Shilan , Breeze, Charles E. , Bassig, Bryan A. , Sm, Jason Yy Wong, Chung, Lap Ping, Zhang, Xu‐Chao , Caporaso, Neil E. , Chang, Jiang , Ho, Jcm , Momozawa, Yukihide , Kobayashi, Masashi , Okubo, Kenichi , Honda, Takayuki , Kunitoh, Hideo , Watanabe, Shun-ichi, Hamamoto, Ryuji , Goto, Kōichi , Minamiya, Yoshihiro, Wakai, Kenji , Murakami, Yoshinori , Shimizu, Kimihiro , Suzuki, Hiroyuki , Ohtaki, Yoichi , Tanaka, Kazumi , Wu, Tangchun , Wei, Fusheng, Kim, Yeul Hong , Chang, Gee-Chen , Chen, Kuan‐Yu, Chen, Yuh-Min, Park, Jae Yong , Kweon, Sun-Seog, Gao, Yu‐Tang , Schwartz, Ann G. , Gorlov, Ivan , Wu, Xifeng , Yang, Ping , Lam, Stephen , Bojesen, Stig E. , Ji, Bu‐Tian , Wichmann, H. E., Christiani, D.C., Brennan, Paul , McKay, James , Field, John K. , Shete, Sanjay , Marchand, Loı̈c Le, Liu, Geoffrey , Andrew, Angeline S. , Zienolddiny-Narui, Shan, Grankvist, Kjell , Taylor, Fiona, Aldrich, Melinda C. , Jeon, Hyo‐Sung, Hu, Zhibin , Burdett, Laura, Yeager, Meredith, Hutchinson, Amy , Hicks, Belynda , Liu, Jia , Berndt, Sonja I, Wu, Wei , Wang, Junwen , Choi, Jin Eun , Park, Kyong Hwa , Sung, Sook Whan , Tan, Wen , Sihoe, Alan , Choi, Yi Young, Hung, Hsiao-Han , Vermeulen, Roel , Wu, Junjie , Tsai, Fang-Yu , Chan, John K. C., Li, Jihua , Lin, Hsien-Chih, Liu, Jie , Sawada, Norie , Yamaji, Taiki , Wyatt, Kathleen , Qi, T. Y., Li, Xuelian , Ren, Yangwu , Chao, Ann, Zhu, Junjie , Chen, Chih‐Yi , ScD, Chien-Jen Chen, Stevens, Victoria L. , Fraumeni, Joseph F., Lin, Kuang , Walters, Robin G., Chen, Zhengming, Chatterjee, Nilanjan , Gorlova, Olga Y. , Hsiung, Chao A. , Chanock, Stephen J, Rothman, Nathaniel , Kohno, Takashi , Lan, Qing, Kartsonaki, Christiana , Liu, Geoffrey , Field, John K , Matsuo, Keitaro , Wang, Junwen , Bojesen, Stig E , Grankvist, Kjell , Chen, Chih-Yi , Dai, Juncheng , Hung, Rayjean J. , Chen, Kexin , Shu, Xiao-Ou , Choudhury, Parichoy Pal , Lin, Dongxin , Zheng, Wei , Wang, Jiucun , Hu, Wei , Cai, Qiuyin , Hong, Yun‐Chul , Kim, Hee Nam , Wu, Yi-Long Lung Cancer , Richardson, Brian Douglas , Zhang, Tongwu , Wang, Zhaoming , Kim, Jin Hee , Albanes, Demetrius , Shin, Min‐Ho , Chung, Lap-Ping, Yang, Yang , Zheng, Hong , Dai, Hong , Yatabe, Yasushi , Kim, Young‐Chul , Daigo, Yataro , Kamatani, Yoichiro , Kobayashi, Masashi , Hosgood, Howard Dean , WATANABE, Shun-ichi J. , Miyagi, Yohei , Matsumoto, Shingo , Horinouchi, Hidehito , Tsuboi, Masahiro , Takahashi, Atsushi , Goto, Akiteru , Hara, Megumi , Nishida, Yuichiro , Takeuchi, Kenji , Matsuda, Koichi , Murakami, Yoshinori, Suzuki, Hiroyuki , Saito, Motonobu , Machiela, Mitchell J. , Oh, In‐Jae , Lee, Victor , Su, Wu‐Chou , Seow, Adeline , Kweon, Sun-Seog , Liu, Jianjun , Houlston, Richard S. , Tardón, Adonina , Chen, Chu, Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Kiemeney, Lambertus A. , Cox, Angela , Yuan, Jian-Min , Lazarus, Philip J. , Schabath, Matthew B. , Jiang, Shih Sheng , Chen, Chung–Hsing , Hsiao, Chin‐Fu , Yeager, Meredith , Liu, Jia , Berndt, Sonja I. , Li, Yuqing , Kang, Chang Hyun , Wang, Wen‐Chang , Xu, Jun, Guan, Peng , Yu, Chong‐Jen , Yang, Gong , Park, In Kyu , Cheng, Iona C. , Song, Bao, Wyatt, Kathleen , Ma, Hongxia , Zhu, Meng , Wang, Yifan , Qi, Tianchen, Iwasaki, Motoki , Wu, Guoping , Yang, Pan‐Chyr , Walters, Robin G. , Chatterjee, Nilanjan , Amos, Christopher I. , Shen, Hongbing , Rothman, Nathaniel , Lan, Qing , Zhang, Haoyu

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 18, 2025 | Volume: 118 | Issue: 2 | Pages: 231-249

10.1093/jnci/djaf272 | PMID 41032288 Get It

Abstract Background Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.
Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
Woolf, Emily K. , Diktas, Hanim E. , Acosta, Andrés , Apolzan, John W. , Ard, Jamy D. , Boyle, Kristen E. , Katzmarzyk, Peter T. , Nicastro, Holly L. , Redman, Leanne M. , Stephens, Jacqueline M. , Martin, Corby K. , Katzmarzyk, Peter T , Phelan, Suzanne , Redman, Leanne , Roe, Brian E , Stephens, Jacqueline M , Tate, Deborah F , Apovian, Caroline M , Martin, Corby K , Acosta, Andres , Gilbert, Jack A. , Laurienti, Paul J. , Lobstein, Tim , Ordovás, José María , Ryan, Donna H. , Tate, Deborah F.

Mayo Clinic

Obesity | September 18, 2025 | Volume: 33 | Issue: 11 | Pages: 2029-2045

10.1002/oby.70015 | PMID 40964812 Get It

ABSTRACT Precision medicine approaches have gained attention for their potential to more effectively manage obesity by tailoring diagnosis and treatment strategies to individual characteristics, including genetic background, phenotypes, metabolic profiles, and environmental exposures. The current review evaluates the evidence for precision medicine in weight management by summarizing the proceedings of a Pennington Biomedical Scientific Symposium titled “Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?” This review discusses the extent to which we can classify and predict obesity risk based on individual‐level factors; whether we have the diagnostic capability to prospectively identify people who will benefit most from specific interventions; whether prospective trials demonstrate superior prevention and treatment of obesity when precision approaches are applied; and whether evidence is sufficient to guide policy decisions. Expert opinions were presented on the current evidence of precision medicine for obesity to collectively evaluate key barriers and opportunities for implementation of precision approaches in clinical and public health settings.
A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions
Manzano, Giovanna S. , Balaban, Denis , Zhang, Yihan , Healy, Brian C. , Chwalisz, Bart K. , Levy, Michael , Venna, Nagagopal, Stern, Barney J. , Pardo, Carlos A. , Rjeily, Nicole Bou , Redenbaugh, Vyanka , Aksamit, Allen J. , Herman, Max Joseph, Rodriguez, Elsa, Snider, Laura, Rains, Hannah G , Montalvo, Mayra , Ramirez, Sergi Martinez, Horta, Lucas, Clardy, Stacey , Cho, Tracey , Samudralwar, Rohini, Torres, Noellie Rivera, Clifford, David B. , Majed, Masoud , Zabeti, Aram , Marcucci, Samuel , Mao‐Draayer, Yang , Doty, John D. , Agyei, Paunel, Bhattacharyya, Shamik , Berger, Joseph R. , Samudralwar, Rohini D , Dunham, S Richard , Levy, Michael , Clardy, Stacey L , Bhattacharyya, Shamik , Manzano, Giovanna Sophia , Balaban, Denis T , Cho, Tracey A , Pardo, Carlos A , Venna, Nagagopal , Barreras, Paula , Flanagan, Eoin P. , Hutto, Spencer K , Herman, Max, Sammak, Sally El , Snider, Laura, Rempe, Torge , Ramirez, Sergi Martinez, Lord, Jennifer, Abdel-Wahed, Lama , Torres, Noellie Rivera, Dunham, Steven , Doty, Jon

Mayo Clinic

Annals of Clinical and Translational Neurology | September 18, 2025 | Volume: 12 | Issue: 12 | Pages: 2589-2599

10.1002/acn3.70200 | PMID 40963302 Get It

ABSTRACT Objective The optimal treatment for neurosarcoidosis myelitis is uncertain. We characterize incident neurosarcoidosis myelitis and assess treatment response by MRI and clinical scales. Methods Incident probable or definite neurosarcoidosis myelitis in adults was retrospectively identified from 13 academic medical centers. Cases were analyzed by initial treatment. The primary outcome was T1 post‐contrast gadolinium enhancement resolution at 6 months post‐treatment. Secondary outcomes were changes in modified Rankin scale (mRS) and Expanded Disability Status Scale (EDSS) from nadir to final follow‐up. Results Two hundred two patients were identified (median diagnosis age: 47 years (IQR 39–55); male: female 1.3:1). Median nadir mRS and EDSS were 2 (IQR 2–3) and 4 (IQR 2.5–6). At initial treatment, 129 (63.9%) received prolonged corticosteroids ≥ 4 weeks (group A 1 ), 36 (17.8%) received corticosteroids < 4 weeks (B 1 ), 21 (10.4%) received corticosteroids plus sarcoidosis‐directed immunosuppressant (E), and 16 (7.9%) received corticosteroids plus non‐sarcoidosis‐directed agents (F). In 167 cases with sufficient imaging, there were no significant differences in contrast enhancement resolution at 6 months (A 1 27/106 (25.5%), B 1 9/28 (32.1%), E 5/19 (26.3%), F 5/14 (35.7%); Fisher's exact p = 0.76). There were no significant differences in changes in mRS or EDSS among treatment groups (Kruskal–Wallis p = 0.69 and 0.63, respectively) after median follow‐up of 46.5 months (IQR 18–91.3). Interpretation Different initial immunosuppression strategies did not correlate with MRI contrast enhancement resolution at 6 months or clinical scales (mRS, EDSS). However, conclusions are limited by retrospective design, imbalanced cohorts, and insensitivity of binary MRI outcomes and available clinical scales for treatment response in neurosarcoidosis.
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children
Almond, Christopher S. , Alejos, Juan , Ameduri, Rebecca , Barkoff, L., Barnes, Aliessa, Butto, Arene , Carlo, Waldemar F. , Chrisant, Maryanne , Dreyer, William J. , Everitt, Melanie D. , Gonzales, S., Hollander, Seth A. , Kindel, Steven J. , Klein, Gloria L., Lamour, Jacqueline M. , Lee, Joanne , Lü, Minmin , Lytrivi, Irene D. , Miyamoto, Shelley D. , Pahl, Elfriede , Peng, David M. , Sutcliffe, David , Ybarra, A., Zangwill, Steven , Rossano, Joseph W. , Investigators, TEAMMATE Trial, Choi, Jua , Wilber, Jared, Sutherland, Scott M. , Feng, Dana, Lagerborg, Kendra, Burns, Julia, Nikolli, Kledja, Twombly, Adrianna, Massey, Linda K., Wartick, Jennifer, Yohannes, Kifle, Gupta, Akanksha , Major, Melissa , Blume, Elizabeth D. , Esteso, Paul , VanderPluym, Christina , Bastardi, Heather , MacLean, Matthew T. , Haschke, Paul, Gibbons, Taylor , Vu, Courtney , Reilly, Sydney, Ha, Lynne, Boyle, Carley, Robie, Sharon L., Ogata, Kay, Knecht, Carlos, Browne, Lorna P. , Malone, LaDonna J. , Gordon, Megyn, Molina, Kimberly , Cabrera, Antonio G. , Lambert, Linda, Fullerton, Chase, Thompson, Kate J., Cardon, Michelle, Timmer, Amanda, Nelson, Michelle , Ramstack, Dani, Heyrend, Carly, Benefield, Emily C., Roberson, Teresa, Butts, Ryan J. , Martinez, Maria , Pottorre, Simi, Burgardt, Laura, Armstrong, Blake, Zamberlan, M. , McCormick, Amanda D. , Bartsch, Jaynee, Mahle, William T. , Burnett, Meilssa, Pietra, Biagio A. , Breault, Leah, Friedland‐Little, Joshua , Prakash, Ranjini, Lee, Anne CC , Brody, Linnea, Huberts, Avery, Noon, Kelli, Guadiz, Donna, Garcia, Allison, Addonizio, Linda J. , Repp, Arielle, Cornelius, C.E. , Abraham, Margaret, Rose-Felker, Kristen, Moninger, Allison, Huston, Allison, Berman, Pamela, Ploutz, Michelle , Wisotzkey, Bethany , Grohall, Stacey, Colon, April, Churosh, Jenny, Cordova, Renee, Smith, Paulette, Kornetsky, Susan , Mitchell, Anna, Alderson, Daniel, Dominguez, R Blanco, Gawlowicz, Kennan, Lipsitz, Stuart R. , Eisen, Howard J. , Jeewa, Aamir , Uber, Patricia A., Thakar, Rahul, Ellsworth, Darrell L. , McCormick, A , Peng, D M , Daly, Kevin P , Albers, Erin L. , Auerbach, Scott R. , Bock, Matthew J. , Castleberry, Chesney , Deshpande, Shriprasad R. , Feingold, Brian , Lal, Ashwin K. , Ryan, Thomas D. , Singh, Tajinder P. , Su, Jennifer A. , Sleeper, Lynn A. , Investigators, TEAMMATE Trial, Wilber, Jared, Nikolli, Kledja, Massey, Linda, Wartick, Jennifer, Major, Melissa, MacLean, Matthew, Lee, JungWoo, Joong, Anna , Reilly, Sydney, Kuhn, Michael, Ogata, Kay, Knecht, Carol, Gordon, Megyn, Hansen, Lisa, May, Lindsay J. , Lambert, Linda, Fullerton, Chase, Thompson, Kate, Timmer, Amanda, Heyrend, Carly, Martinez, Maria, Schumacher, Kurt R. , Lim, Heang M. , Bartsch, Jaynee, Burnett, Meilssa, Prakash, Ranjini, Lee, Anne CC , Brody, Linnea, Huberts, Avery, Noon, Kelli, Guadiz, Donna, Repp, Arielle, Bansal, Neha , Hsu, Daphne T. , Cornelius, Chelsea, Padilla, Luz A. , Churosh, Jenny, Cordova, Renee, Mitchell, Anna, Alderson, Daniel, Dominguez, Robleinscky, KOBASHIGAWA, JON A. , Wightman, Aaron G.

Mayo Clinic

JAMA | September 17, 2025 | Volume: 334 | Issue: 15 | Pages: 1339

10.1001/jama.2025.14338 | PMID 40960806 Get It

ImportanceStudies suggest that everolimus may reduce the risk of rejection, cardiac allograft vasculopathy (CAV), chronic kidney disease (CKD), and cytomegalovirus (CMV) after heart transplant. Everolimus use is controversial because of data demonstrating higher infection deaths when everolimus is introduced de novo after transplant. It is unclear whether everolimus is safe and effective when initiated at 6 months posttransplant in children, a population in which median graft survival is limited to 15 years and randomized clinical trials are lacking.ObjectiveTo evaluate the safety and efficacy of everolimus combined with low-dose tacrolimus to prevent major adverse transplant events (MATEs) in children after heart transplant.Design, Setting, and ParticipantsMulticenter, randomized, open-label, clinical trial enrolling 211 patients who were alive 6 months after pediatric heart transplant at 25 US sites from February 2018 to August 2020. The last date of follow-up was April 17, 2023.InterventionsParticipants were randomized to receive everolimus and low-dose tacrolimus (n = 107) or standard-dose tacrolimus and mycophenolate mofetil (n = 104) for 30 months.Main Outcomes and MeasuresThe primary efficacy end point was the MATE-3 score at 30 months, a validated composite ordinal end point including acute cellular rejection, CAV, and CKD. The primary safety end point was the MATE-6 score, encompassing the MATE-3 score plus antibody-mediated rejection, infection, and posttransplant lymphoproliferative disorder.ResultsAmong 211 children randomized, the mean age was 8.2 (SD, 6.3) years, 97 (46%) underwent transplant for congenital heart disease, and 49 (23%) were treated for rejection before 6 months. At 30 months, the mean MATE-3 score did not differ between the 2 treatment groups (mean difference, −0.32; 95% CI, −0.90 to 0.20; P = .16). The mean MATE-6 score was no higher in the everolimus group than in the mycophenolate group (baseline-adjusted mean difference, −0.40; 95% CI, −1.81 to 0.93), meeting the success criterion for safety (noninferiority margin &amp;lt;3). There were no differences in graft survival, MATE-free survival, or freedom from any individual MATE. Everolimus was associated with greater improvement in estimated glomerular filtration rate at 12 months (mean difference, 10.5 mL/min/1.73 m2; 95% CI, 1.09-19.91 mL/min/1.73 m2) and a lower incidence of CMV infection (hazard ratio, 0.50; 95% CI, 0.26-0.93).Conclusions and RelevanceAmong 6-month pediatric heart transplant survivors, everolimus and low-dose tacrolimus did not differ from tacrolimus and mycophenolate in preventing the composite of cellular rejection, CAV, and CKD at 30 months. However, everolimus and low-dose tacrolimus appear to be safe based on the total burden of 6 MATEs and may be associated with improved kidney function and less CMV infection.Trial RegistrationClinicalTrials.gov Identifier: NCT03386539
Functional Connectivity Associations With Markers of Disease Progression in GRN Pathogenic Variant Carriers
Flagan, Taru , Chu, Stephanie A. , Häkkinen, Suvi , McFall, David , Brown, Jesse A. , Fernhoff, Kristen, Rankin, Katherine P. , Mandelli, Maria Luisa , Gorno‐Tempini, Maria Luisa, Yokoyama, Jennifer S. , Sturm, Virginia E. , Foroud, Tatiana, Geschwind, Daniel H., Ghoshal, Nupur , Graff‐Radford, Neill R., Huang, Eric J. , Huey, Edward D. , Kantarci, Kejal , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Petrucelli, Leonard , Ramos, Eliana Marisa , Roberson, Erik D. , Toga, Arthur W. , Weıntraub, Sandra , Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L., Rosen, Howard J. , Miller, Bruce L., Moreno, Fermín , Seeley, William W., Lee, Suzee E. , Flagan, Taru M , Rohrer, Jonathan D , Kantarci, Kejal , Tartaglia, Maria Carmela , Roberson, Erik , Yokoyama, Jennifer , Zhang, Liwen , Rohrer, Jonathan D. , Lee, Alex J. , Pasquini, Lorenzo , Gorno‐Tempini, Maria‐Luisa, Appleby, Brian S. , Dickerson, Bradford Clark , Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Graff‐Radford, Neill R. , Hsiung, Ging‐Yuek Robin , Litvan, Irene , Rojas, Julio C. , Boeve, Bradley F. , Boxer, Adam L.

Mayo Clinic

Annals of Clinical and Translational Neurology | September 17, 2025 | Volume: 12 | Issue: 12 | Pages: 2575-2588

10.1002/acn3.70170 | PMID 40958169 Get It

ABSTRACT Objective Autosomal dominant progranulin ( GRN ) pathogenic variants are a genetic cause of frontotemporal lobar degeneration. Though clinical trials for GRN ‐related therapies are underway, there is an unmet need for biomarkers that can predict symptom onset and track disease progression. We previously showed that asymptomatic GRN variant carriers exhibit thalamocortical hyperconnectivity that increases with age, presumably as they are approaching symptom onset. Whether hyperconnectivity arises concomitantly with markers of neurodegeneration remains unclear. Methods Utilizing T1 and task‐free functional magnetic resonance imaging from 49 asymptomatic and 26 symptomatic GRN variant carriers, we determined the relationships between functional connectivity, as measured by voxelwise whole‐brain degree, and GRN ‐relevant markers of disease progression, including plasma neurofilament light chain concentrations, cerebrospinal fluid complement C1q and C3b protein levels, obsessive‐compulsive disorder symptom severity, and gray matter volume. Results Neurofilament light chain concentrations were associated with frontotemporoparietal and thalamic hyperconnectivity in asymptomatic GRN variant carriers and extensive regions of atrophy in symptomatic carriers. Complement levels were associated with regions of hyperconnectivity, but not gray matter volume, in symptomatic carriers. Obsessive‐compulsive disorder symptom severity was associated with hypoconnectivity across all GRN carriers. Asymptomatic carriers with thalamic hyperconnectivity tended to have lower gray matter volume in the bilateral insula and left lateral parietal cortex, early regions of atrophy in GRN ‐frontotemporal dementia. Interpretation In asymptomatic carriers, the co‐occurrence of hyperconnectivity, high neurofilament light chain, and low gray matter volume suggests that functional hyperconnectivity may portend the onset of clinical decline. These findings point toward hyperconnectivity as an indicator of approaching symptomatic onset.
Deep Decisions: Navigating Stroke Risk And Safe Diving In A Patient With Patent Foramen Ovale And History Of Decompression Illness
Tayon, Kevin G. , Carlisle, Ashley E., Shapiro, Kathryn A., Pollak, Peter , Shapiro, Brian P. , Shapiro, Kathryn A., Dineen, Elizabeth H. , Taylor, Bryan J.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 16, 2025 | Volume: 57 | Issue: 10S | Pages: 286-286

10.1249/01.mss.0001157052.31580.83 Get It

Interventional High Monoenergetic Spectral CT for Percutaneous Thermal Ablation Procedures
Parvinian, Ahmad , Huber, Nathan R. , Musa, Juna , Ferrero, Andrea , Welch, Brian T. , Favazza, Christopher , Hibbert, Rebecca , Adamo, Daniel A. , Favazza, Christopher P, Huber, Nathan Robert

Mayo Clinic

Journal of Computer Assisted Tomography | September 16, 2025 | Volume: 50 | Issue: 1 | Pages: 113-117

10.1097/rct.0000000000001786 | PMID 40954035 Get It

Objective: The purpose of this study was to evaluate the potential clinical value of spectral CT for image guidance during percutaneous thermal ablation, particularly investigating high monoenergetic (MonoE) for metal artifact reduction. Materials and Methods: A phantom experiment was performed in which an ablation probe was scanned in “continuous CT” (CCT) mode on a spectral CT scanner. ROI measurements quantified metal artifacts for conventional and MonoE CCT images. Subsequently, a retrospective reader study was conducted with 10 patient cases. Three radiologists reviewed cases to select the optimal MonoE setting and perform a Likert score rating (+2: MonoE preferred, −2: conventional preferred). Results: Phantom measurements indicated a reduction in metal artifact for high MonoE (150 keV: −46 HU) relative to conventional CCT (−122 HU). The MonoE setting preference was 151±21 keV. The mean Likert score was 1.2±0.7. Radiologists indicated a perceived benefit of high MonoE CCT when probe placement was near a critical structure. Conclusions: This study indicates a clinical preference for high MonoE CCT compared with conventional CCT. Insofar as spectral CCT can be offered at a clinically feasible time frame, our results support the assessment of 150 keV image to reduce metal artifact while maintaining satisfactory soft tissue contrast.